Last updated: July 30, 2026
Executive summary
- Case: Mallinckrodt IP LLC v. B. Braun Medical Inc. 1:17-cv-00365 (federal district court).
- Parties: Mallinckrodt IP LLC (plaintiff) vs. B. Braun Medical Inc. (defendant).
- Core dispute: Patent enforcement tied to ANDA-style market entry and related IP around a Mallinckrodt-branded pharmaceutical product.
- Business impact: Outcomes typically determine whether B. Braun can launch a generic or whether launch is blocked pending patent expiry, injunctions, or settlement.
- Limitation: A complete, accurate litigation summary requires docket-verified specifics (asserted patent numbers, claim construction rulings, trial dates, settlement/injunction terms, and dispositive orders). No such case-record details are included in the prompt.
What happened in Mallinckrodt IP v. B. Braun Medical Inc. (1:17-cv-00365)?
A litigation summary must be grounded in docket events (complaint filing date, answer, amended pleadings, Markman, summary judgment, injunction orders, and any settlement or dismissal entries). Without those docket facts, an accurate narrative cannot be produced.
Which patents were asserted in 1:17-cv-00365?
Patent-by-patent identification is required to analyze scope, strength, and design-around risk. The asserted-patent list is not provided in the prompt.
What product and regulatory submission triggered the suit?
These suits typically map to an FDA submission (ANDA for small molecules; or a biologics license pathway, though “medical inc.” cases more often involve ANDAs). The specific FDA application number, drug name, strength, and dosage form are not provided.
What remedies were sought (injunction, damages, attorneys’ fees)?
Remedy posture depends on the pleading stage and any adjudicated findings (willfulness, infringement, validity). The requested summary requires those docket-anchored details.
What patent issues drove the litigation (infringement, invalidity, enforceability)?
A defensible analysis depends on the actual briefing record: which invalidity grounds were asserted (anticipation, obviousness, lack of enablement, written description, indefiniteness, §101), and what infringement theory was used (literal vs. doctrine of equivalents, method vs. composition).
Infringement theory: product-by-process, method-of-use, or composition claims?
Litigation strategy changes if the case targets:
- composition/formulation claims (excipient ratios, particle size, pH buffers, etc.)
- method-of-use claims (indication-specific dosing regimens)
- manufacturing/process claims (steps, temperatures, sterilization parameters)
No claim-category information is present in the prompt.
Validity challenges: the exact prior art and claim chart posture
Strength analysis requires:
- asserted publication/patent references
- whether those were used in summary judgment or only at trial
- outcome (invalidation vs. survival)
No prior-art list or rulings are provided.
What is the procedural posture of Mallinckrodt IP v. B. Braun (1:17-cv-00365)?
Procedural posture includes:
- whether the case reached claim construction (Markman)
- whether summary judgment occurred
- whether a final judgment issued
- whether the parties settled and the case was dismissed with or without prejudice
The prompt provides no docket milestones, dates, or order outcomes.
When does the Mallinckrodt estate for this product expire, and how does exclusivity affect generic entry?
Exclusivity and expiration analysis require:
- the specific Orange Book-listed patents for the asserted drug
- whether they are listed as drug substance, drug product, or method-of-use
- their expiration dates (including pediatric exclusivity and patent-term adjustments)
- whether there is any §156 extension and when
No Orange Book listing details or patent expiry dates are provided.
What is the Orange Book status of Mallinckrodt patents involved in this case?
A credible Orange Book status section must cite:
- listed NDA/ANDA numbers
- patent numbers
- expiration and exclusivity codes
- any delisting events
The prompt includes no drug identity or Orange Book data.
How do Paragraph IV challenges factor into this litigation?
Paragraph IV challenges depend on the defendant’s ANDA certification and the notice of paragraph IV (PIV) served on the brand. Case analysis requires:
- ANDA number
- certification letter
- whether it was “IV” for some patents and “I/II/III” for others
- whether a settlement occurred under Hatch-Waxman
None of that is included.
Did B. Braun launch or be blocked by injunction in this case?
Launch risk is determined by:
- injunction scope and effective date
- whether any automatic stay under 21 U.S.C. §355(j)(5)(B)(iii) applied
- whether a court enjoined importation, distribution, or generic marketing
No injunction or launch facts are supplied.
What settlement outcomes are typical for Mallinckrodt IP cases like this, and what terms matter?
Settlement analysis requires the actual agreement terms or docket orders that reflect:
- end-of-stay dates
- design-around obligations
- permitted launch dates by dosage form/strength
- royalties, lump sums, and “agreed entry” triggers
- dismissal with prejudice and scope of release
The prompt provides no settlement details.
How strong is the patent estate behind Mallinckrodt’s asserted claims?
Strength assessment is claim-specific and requires:
- claim scope (independent claim breadth)
- prosecution history (narrowing amendments, disclaimers)
- claim construction outcomes
- infringement evidence (samples, test reports, specifications)
- validity ruling outcomes and standard-of-proof findings
No asserted claims, constructions, or rulings are provided.
What generic entry risks exist for B. Braun if the case ends without a final adjudication?
Entry risk depends on whether the case was:
- dismissed (and why)
- settled (and with what entry calendar)
- still pending on appeal
The prompt provides no final disposition.
How does Mallinckrodt v. B. Braun compare with other Mallinckrodt IP patent fights?
A comparison requires a list of related cases (same drug or same patent family) and their outcomes, including:
- which defendants faced injunctions
- which patents were invalidated
- whether settlements shifted launch timing
No cross-case data is provided.
Key litigation facts table (to be filled from docket record)
| Field |
Required to complete analysis |
Status in prompt |
| Court |
District and judge |
Not provided |
| Filing date |
Complaint filed |
Not provided |
| Asserted patents |
Patent numbers and families |
Not provided |
| Drug/NDA/ANDA |
Product name and application IDs |
Not provided |
| Claim categories |
Composition vs method-of-use vs process |
Not provided |
| PIV basis |
ANDA certifications and notice |
Not provided |
| Markman |
Claim construction results |
Not provided |
| Dispositive orders |
Summary judgment/validity/infringement rulings |
Not provided |
| Injunction |
Whether granted and scope |
Not provided |
| Settlement |
Terms and effective dates |
Not provided |
| Final disposition |
Judgment/dismissal status and prejudice |
Not provided |
Key Takeaways
- A complete litigation summary for Mallinckrodt IP LLC v. B. Braun Medical Inc., 1:17-cv-00365 must reference docket specifics: asserted patent numbers, procedural orders, claim construction, and judgment/settlement terms.
- The prompt does not provide the case-record facts needed to produce an accurate, high-stakes analysis tied to enforceability, infringement scope, exclusivity timing, or generic entry.
FAQs
- What patents are typically asserted in Mallinckrodt IP Hatch-Waxman suits, and how are they categorized (drug substance, drug product, method-of-use)?
- How do claim construction outcomes usually affect infringement and invalidity in ANDA-related patent cases involving Mallinckrodt?
- What injunction scopes are common when a district court finds infringement in a Paragraph IV dispute?
- How do settlements in Hatch-Waxman cases usually set launch dates and design-around constraints for defendants like B. Braun?
- How does pediatric exclusivity and patent-term adjustment change the “day-one” timeline for generic entry?
References
- (No sources cited. The prompt does not include docket documents, court orders, or Orange Book identifiers.)
